GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Maxigen Biotech 1783.TW · TWD

Consumer Staples · Taiwan Stock Exchange · 🇹🇼 Taiwan

Compare

35.25

+1.59%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Maxigen Biotech

Its shares trade on Taiwan Stock Exchange under the ticker 1783.TW. It has been listed since 18 May 2011. In the fiscal year to 31 December 2025, it reported revenue of TWD 811.6m and net income of TWD 265.3m. At that date it held total assets of TWD 1.89bn and shareholders' equity of TWD 1.54bn.

Maxigen Biotech, Inc. engages in the research, development, manufacturing, and sales of biomedical materials and beauty care products. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2011-05-18. The firm operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Consumer Staples
Industry
Personal Products
Listed since
18 May 2011
Website
mbi-bio.com ↗

Leadership

Pay as last reported

  • Mr. Yung-Hsiang LinChairman of the Board, since 2021
  • Mr. Jingting ChenGeneral Manager, Director, since 2021
  • Qixiang ChenSenior Deputy General Manager
  • Yijun HuangDeputy General Manager
  • Ruiyi WuHead of Finance & Accounting
  • Shiming LaiDirector
  • Chi-Jui LiDirector
  • Congjie QiuDirector
  • Shih-an ChenIndependent Director
  • Mr. Sung-Yuan LiaoIndependent Director
  • Zhongming ZengIndependent Director
  • Yanjuan ChenIR Contact Officer, since 2024

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Maxigen Biotech Inc possesses several strengths that contribute to its success in the biotech industry. These include:

Weaknesses

  • Despite its strengths, Maxigen Biotech Inc also faces certain weaknesses that need to be addressed in order to maintain its competitive edge:

Opportunities

  • Maxigen Biotech Inc can take advantage of various opportunities to grow and expand its business:

Threats

  • Maxigen Biotech Inc faces certain external threats that pose challenges to its operations:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.